Page 2 - Als Progression News Today

Researchers using machine learning find neurodegenerative disease progression can fall into newly identified patterns. The work, led by members of the MIT-IBM Watson AI Lab, may help predict patient prognoses, inform clinical trial designs, and discover underlying disease causes.

The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.

In a recent study of patients with early relapsing-remitting MS or clinically isolated syndrome, almost two thirds of confirmed disability accumulation occurred independently of relapses.

Autologous hematopoietic stem cell transplantation for the treatment of active secondary progressive MS is associated with better disability outcomes than other immunotherapies, a new Italian study suggests.

Updated European guidelines also include a recommendation for siponimod in progressive MS and more detailed information on drug use in pregnancy.

Different prognostic variables come together into a single predictive score.

Rituximab reduced relapses and MRI activity more effectively than dimethyl fumarate, natalizumab, and injectable therapies in a recent study. Disability did not differ between treatments, however.

Twenty-five year data show a positive shift towards earlier diagnosis and treatment of multiple sclerosis and improved prognosis over time.

Partly hung up in fda regulations and cost prohibitive. tens of millions of dollars to conduct one phase of a trial like this. the team at emery are currently working to raise the funds for the third phase of this trial. but its risk and reward. even slow progress is still progress. >> now that we understand the limitations of having done this the first time were developing techniques to try and inject the spinal cord in the mri scanner so theres a lot of details, questions that we would have ne...

Latest updates on this topic.